Implication de la signalisation du BCR dans le ciblage thérapeutique des lymphomes folliculaires [PDF]
, 2010 Une des molécules clés des fonctions biologiques du lymphocyte B est le BCR (B Cell Receptor). Les connaissances concernant l'altération du signal BCR et son implication dans l'apparition des lymphopathies B ne cessent de s'élargir.
Kheirallah, Samar
core
American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez +17 more
wiley +1 more source
Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis. [PDF]
Sci Rep, 2023 Nguyen TT +7 more
europepmc +1 more source
Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine
Journal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl +3 more
wiley +1 more source
Pharmacogenomic Analyses Implicate B Cell Developmental Status and <i>MKL1</i> as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy. [PDF]
Cells, 2023 Small GW +10 more
europepmc +1 more source
ACR Open Rheumatology, Volume 8, Issue 8, August 2026.Objective To evaluate the six‐month effectiveness and safety of rituximab biosimilars compared to the originator in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and outcomes following originator to biosimilar switching. Methods We recruited adults with GPA or MPA treated with the rituximab originator or a biosimilar for ...
Arielle Mendel +14 more
wiley +1 more source
Effects of anti-bursin monoclonal antibody on immunosuppression in the duck (Cherry Valley duck) [PDF]
, 2006 To study the immunologic function of bursin, we analyzed the effects of anti-bursin monoclonal antibody (mAb) on the immunosuppression in ducks (Cherry Valley duck) by injecting various doses of the anti-bursin mAb into 13-d duck embryos.
Guo, S +5 more
core
Drug Design, Development and TherapySarah-Jane Martin,1,2 Melanie Guenette,1 Jiwon Oh1 1Division of Neurology, Department of Medicine, St Michael’s Hospital, Toronto, Canada; 2University of Glasgow, Glasgow, UKCorrespondence: Jiwon Oh, Email jiwon.oh@unityhealth.toAbstract: B cells are ...
Martin SJ, Guenette M, Oh J
doaj
A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance
Advanced Science, Volume 13, Issue 43, 3 August 2026.A stable Os(III)/Os(IV) redox couple is developed to disrupt the tumor cell redox balance by concurrently catalyzing ROS generation and GSH depletion. Osmium‐treated cells exhibit multiple cell death pathways, including apoptosis, ferroptosis, and immunogenic cell death.
Wan‐Qiong Huang +9 more
wiley +1 more source
Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia [PDF]
, 1999 Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission.
Vartholomatos, G. +5 more
core